Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.50 |
| ▸ | PDE4A | P27815 | 7/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152321 | 0.90 | SCN9A (0.49) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL24969558 | 0.90 | SCN9A (0.49) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL20189249 | 0.89 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL28033753 | 0.87 | PDE4B (0.59) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL20463367 | 0.86 | SLC6A9 (0.53) | PDE4BPDE4DPDE4APDE4CLMNA | |
| SCHEMBL2090601 | 0.84 | PDE4B (0.60) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL4278555 | 0.84 | PDE4B (0.63) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL15968784 | 0.84 | LMNA (0.55) | PDE4BPDE4DPDE4APDE4CLMNA | |
| SCHEMBL1871388 | 0.83 | PDE4B (0.47) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL3416298 | 0.83 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | PDE4B 353/4885PDE4D 472/4885PDE4A 287/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | PDE4B 437/4885PDE4D 620/4885PDE4A 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.